Biocompatible nanocomposite for PET/MRI hybrid imaging

Area of Science:

• Nanotechnology
• Biomedical Engineering
• Oncology

Background:

• Early cancer diagnosis and treatment remain critical challenges.
• Advanced nanocarrier systems offer potential for improved diagnostic and therapeutic outcomes.

Purpose of the Study:

• To design and develop a novel nanocarrier system for early cancer diagnosis and treatment.
• To integrate magnetic resonance imaging (MRI) and positron emission tomography (PET) functionalities into a single nanocarrier.

Main Methods:

• Synthesized superparamagnetic maghemite nanoparticles (NPs) coated with a lipophilic ligand.
• Entrapped NPs into biodegradable poly(lactic-co-glycolic acid)-polyethylene glycol polymeric NPs.
• Conjugated NPs with a chelating ligand for Gallium-68 ((68)Ga) incorporation.
• Evaluated in vitro cytotoxicity using human pancreatic cancer cells.
• Performed in vivo biodistribution studies using positron emission tomography-computed tomography (PET-CT) in healthy animals.

Main Results:

• The nanocarrier system was successfully synthesized and characterized.
• In vitro assays confirmed the cell viability of human pancreatic cancer cells upon exposure to the nanosystem.
• In vivo biodistribution studies provided insights into the nanocarrier's behavior in a living organism.

Conclusions:

• The developed nanocarrier system holds potential for early cancer diagnosis and treatment.
• The combination of MRI and PET imaging capabilities in a single nanocarrier could enhance diagnostic accuracy.
• Further studies are warranted to evaluate its efficacy and safety in cancer models.